| Chapter title |
Endocannabinoids
|
|---|---|
| Chapter number | 4 |
| Book title |
Endocannabinoids
|
| Published in |
Handbook of experimental pharmacology, January 2015
|
| DOI | 10.1007/978-3-319-20825-1_4 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-920824-4, 978-3-31-920825-1
|
| Authors |
Fowler, Christopher J, Christopher J. Fowler |
| Editors |
Roger G. Pertwee |
| Abstract |
The endocannabinoids anandamide and 2-arachidonoylglycerol are metabolised by both hydrolytic enzymes (primarily fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)) and oxygenating enzymes (e.g. cyclooxygenase-2, COX-2). In the present article, the in vivo data for compounds inhibiting endocannabinoid metabolism have been reviewed, focussing on inflammation and pain. Potential reasons for the failure of an FAAH inhibitor in a clinical trial in patients with osteoarthritic pain are discussed. It is concluded that there is a continued potential for compounds inhibiting endocannabinoid metabolism in terms of drug development, but that it is wise not to be unrealistic in terms of expectations of success. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Unknown | 41 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 24% |
| Student > Ph. D. Student | 9 | 21% |
| Other | 6 | 14% |
| Student > Bachelor | 4 | 10% |
| Professor | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 6 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 17% |
| Biochemistry, Genetics and Molecular Biology | 6 | 14% |
| Medicine and Dentistry | 6 | 14% |
| Agricultural and Biological Sciences | 5 | 12% |
| Neuroscience | 3 | 7% |
| Other | 2 | 5% |
| Unknown | 13 | 31% |